PA
ELDN icon

Perceptive Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Perceptive Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,081
Closed -$3.64M – 202
2016
Q2 		$3.64M Buy
4,081
+1,085
+36% +$1.2M 0.25% 70
2016
Q1 		$2.72M Hold
2,996
– – 0.24% 78
2015
Q4 		$4.23M Hold
2,996
– – 0.31% 58
2015
Q3 		$5.02M Hold
2,996
– – 0.4% 59
2015
Q2 		$6.46M Buy
2,996
+167
+6% +$323K 0.39% 57
2015
Q1 		$5.48M Sell
2,829
-167
-6% -$368K 0.43% 48
2014
Q4 		$7.15M Buy
2,996
+1,885
+170% +$4.48M 0.6% 41
2014
Q3 		$2.73M Buy
+1,111
New +$3.16M 0.28% 62

Other funds holding ELDN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EA
Emerald Acquisition Seattle, Washington $51.8B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors's ELDN Position: Q3 2016 in Review

Perceptive Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q3 2016, closing a stake of 4,081 shares — an estimated $3.64M sold.

Perceptive Advisors first reported a position in ELDN in Q3 2014 and held it in 8 quarters. The position peaked at $7.15M in Q4 2014. 44 funds tracked by Wall St. Rank hold ELDN as of Q3 2016.

  • Perceptive Advisors reported no remaining Eledon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Perceptive Advisors sold 4,081 Eledon Pharmaceuticals shares in Q3 2016, an estimated $3.64M.
  • Perceptive Advisors first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 8 quarters.
  • Perceptive Advisors's Eledon Pharmaceuticals position peaked at $7.15M in Q4 2014.
  • 44 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2016.

Based on Perceptive Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.